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Abstract
Background: Psychiatric disorders and use of selective antidepressants during pregnancy can have negative effects
on mother and infant postpartum. This study aimed to provide evidence-based recommendations on observation
of antidepressant-exposed mother-infant dyads.
Methods: In this observational study, mother-infant dyads were observed for possible consequences of either the
maternal psychiatric disorder or fetal exposure to selective antidepressants during pregnancy. These possible
complications can lead to medical interventions, including 1. adjustment of antidepressants 2. admission to the
psychiatric department 3. additional investigations due to indistinctness about the origin of neonatal symptoms
4. treatment of poor neonatal adaptation and 5. consultation of an external organization for additional care. The
type, number and time to medical interventions were analyzed.
Results: In 61% of the 324 included mother-infant dyads one or more intrventions were performed. Adjustment
of antidepressants and treatment of poor neonatal adaptation were most prevalent. In 75% of dyads the final
intervention was performed within 48 h.
Conclusions: The high prevalence and type of medical interventions requires professional observation of all
mother-infant dyads exposed to selective antidepressants. In the absence of specialized home care, hospital
admission is indicated whereby an observational period of 48 h seems sufficient for most dyads.
Keywords: Pregnancy, Withdrawal, Observation, Finnegan, Depression
Background
Exposure to selective antidepressants during pregnancy,
used by 2–9% of Western pregnant women [1, 2], can
have postpartum consequences for mother and infant
[3]. In addition, the maternal psychiatric disorder itself
can also have negative consequences during this period
[4]. Therefore, postpartum hospital observation of se-
lective antidepressant-exposed mothers and their infants
is common practice [3, 5, 6]. Unfortunately there are no
guidelines concerning the type and duration of this
observational period.
Possible consequences of the maternal psychiatric
disorder include an increased risk of prematurity and
low birth weight and a recurrence or worsening of
psychiatric symptoms, which can impair the attachment
between mother and infant [4, 7–11]. Approximately
20–30% of selective antidepressant-exposed infants
develop poor neonatal adaptation due to exposure to
selective antidepressants [3, 12–14]. Poor neonatal
adaptation consists of symptoms of restlessness, such
as feeding and sleeping difficulties, which are mostly
mild and self-limiting. Because symptoms are nonspe-
cific, differentiation from other, more severe, neonatal
pathology such as perinatal infection, can be difficult
[3, 5, 13, 14]. Furthermore, some studies found that ex-
posure to selective antidepressants may elevate the risk
of other maternal and neonatal effects, such as postpar-
tum hemorrhage, prematurity and persistent pulmonary
hypertension of the newborn (PPHN). However other* Correspondence: noera.kieviet@gmail.com1Department of Pediatrics, Psychiatry Obstetrics Pediatrics Expert Center
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studies did not find a relation between exposure to se-
lective antidepressant and these complications [15, 16].
Because the evaluation of possible maternal and neo-
natal effects need medical expertise or medical interven-
tion, in the Netherlands, most caregivers advise hospital
admission of mothers and their infants postpartum.
However, the duration of this period differs per hospital.
Several experts advise an observational period of
48 h, though guidelines or protocols are not available
[5, 12, 17–19]. Evidence-based recommendations on
this subject would improve the quality and uniformity
of care. In order to develop such recommendations,
insight into complications that lead to medical inter-
vention is needed.
This observational study provides insight into the type
and number, as well as the time to medical interventions
during the first days postpartum. From these data,
recommendations can be formulated with respect to
the necessity of professional observation, type of ob-
servational setting and time period of observation.
Methods
Setting
We conducted an observational study in a teaching hos-
pital in Amsterdam, the Netherlands. The psychiatric,
obstetric, pediatric clinic of this hospital is a center of
expertise for pregnancy and psychiatric disorders and
advises women with a psychiatric disorder before, during
and after pregnancy. Primary care givers (mainly general
practitioners, midwifes, obstetricians and psychiatrists)
refer patients to this clinic. Approximately 50% of all
women who visit this clinic live in the catchment area
and deliver in our hospital. In case of home birth, or
birth in another hospital due to capacity problems in
our hospital, within 8hours postpartum these women
are admitted to the maternity ward, together with
their infants.
During hospital admission, nurses, pediatricians, ob-
stetricians and psychiatrists observe, evaluate, support
and treat mother and infant for 72 h. The psychiatrist
evaluates possible psychiatric symptoms in mothers
and adjusts the psychotropic medication if necessary
(changes the dosage or type of psychotropic medication
or starts additional medication). The psychiatrist uses
the hospital anxiety and depression scale (HADS),
which is a validated questionnaire for symptoms of
anxiety and depression and is completed at the first
day postpartum delivery [20, 21]. If psychiatric care
after hospital discharge is too limited or in case social
problems, such as absence of a support system, are
detected external organizations can be consulted. The
obstetrician assesses the physical condition of the
mother and treats complications if necessary. Infants
are physically examined by the pediatrician and treated
in case of pathology. Trained nurses assess poor neo-
natal adaptation in infants with use of the Finnegan
scoring list three times a day [22]. This observational
tool is used to monitor the moment of onset and devel-
opment of symptoms of poor neonatal adaptation. A
Finnegan score of four or higher is an indication for
poor neonatal adaptation [3, 5, 12]. The pediatrician
determines if PNA has been present or absent, based
on the Finnegan scores and physical examination and
observation. In case of indistinctness about the origin
of symptoms, additional testing can be necessary to ex-
clude other neonatal pathology, such as perinatal infec-
tion [3, 5, 13, 14]. When poor neonatal adaptation has
been diagnosed supportive measures such as swaddling
are mostly sufficient. Infants with severe poor neonatal
adaptation (multiple Finnegan scores of ≥ 8 and severe
symptoms such as convulsions) are admitted to the
neonatal care unit and can be treated with phenobar-
bital. Parents are supported by explanation and re-
assurance. Furthermore, the team observes the mother-
infant interaction. If interaction difficulties are present
external organizations can be consulted to provide
family care.
Participants
From January 1st 2007 to December 31st 2012 all
mothers who used selective antidepressants during at
least the last trimester of pregnancy and who were ad-
mitted in our hospital for observation together with their
infants postpartum were included (n = 324). Selective anti-
depressants were defined as selective serotonin reuptake
inhibitors, serotonin norepinephrine reuptake inhibitors,
norepinephrine-dopamine reuptake inhibitors or nor-
adrenergic and specific serotonergic antidepressants.
Tricyclic antidepressants, were not included as these
antidepressants have a different mechanism of action.
However, if mothers used other types of antidepres-
sants or other types of psychotropic drugs in combin-
ation with a selective antidepressants, mothers were
included.
Exclusion criteria were use of illicit drugs [23] or
regular alcohol use of more than two units per week
during last trimester of pregnancy, admission to the
psychiatric department up to delivery and postpartum
transfer to another hospital. In order to create mother-
infant dyads, in case of multiple pregnancies one infant
was randomly selected.
Interventions
Mother-infant dyads were analyzed for medical interven-
tions that had been performed during hospital admission,
all caused by exposure to selective antidepressants or the
maternal psychiatric disorder. These interventions were: 1.
adjustment of psychotropic medication 2. admission to
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the psychiatric department 3. additional investigations due
to indistinctness about the origin of neonatal symptoms
whereby the final diagnose was poor neonatal adaptation.
4. treatment of poor neonatal adaptation and 5. consult-
ation of an external organization for additional family
care. The prevalence of interventions was established by
calculating the percentage of mother-infant dyads in
which one or more interventions were performed. All
base-line characteristics were compared between mother-
infant dyads in which an intervention was performed and
dyads whereby no intervention was performed.
Time to interventions
For the first four interventions the time to intervention
(hours postpartum) was analyzed. For the fifth intervention
(consultation of an external organization for additional
family care) time was not analyzed because organizations
are generally contacted at hospital discharge.
Per mother-infant dyad the time to the final interven-
tion was investigated. This was exclusively done for dyads
in which times of all interventions were known.
The time to intervention was divided into <12 h, 13–24,
25–48, 49–72 and >72 h postpartum. The time to the
intervention ‘treatment of poor neonatal adaptation’ was
defined as the moment of administration of pharmaco-
therapy or the moment of the first Finnegan score of four
or higher in case of supportive treatment. The time to
other interventions was established by the time noted in
the patient files of mother and infant.
In order to examine if there are factors which are asso-
ciated with late time of intervention, all base-line charac-
teristics were compared between mother-infant dyads in
which the final intervention was performed within 48 h
and dyads in which the final intervention was performed
after 48 h postpartum.
Statistical analyses
Data were analyzed by SPSS version 21 (IBM, New York,
USA). In all continuous variables, the mean and standard
deviation were presented in case of a normal distribution.
Otherwise, the median and inter quartile range were pre-
sented. The base-line characteristics of mother-infant dyads
in which an intervention was performed were compared to
the characteristics of dyads in which no intervention was
performed. Continuous, normally distributed variables were
compared with the independent sample t test. Continuous,
skewed variables were compared with the Mann Whitney U
test. Dichotomous or categorical variables were compared
with the chi square test. In case more than 20% of the ex-
pected cell counts were less than five the Fisher exact test
was performed. A result was considered statistically signifi-
cant if the p-value was not larger than 0.05. The base-line
characteristics of dyads in which the final intervention was
performed within or after 48 h were compared in the same
manner. In addition, odds ratios (OR) and 95% confidence
intervals (CI) were estimated using univariate analysis.
Results
Patient characteristics
In the period of January 1st 2007 till December 31st 2012,
a total of 330 mothers who used selective antidepressants
during at least the last trimester of pregnancy were admit-
ted to the maternity ward of our hospital for observation.
Two mothers delivered a twin, one of each twin was ran-
domly excluded. One mother-infant dyad was excluded
because the mother used soft drugs during pregnancy and
five dyads were excluded because they were transferred to
another hospital. In three dyads this transfer was based on
severe medical problems, which were fluxus, neonatal
breathing difficulties and neonatal asphyxia. In the end,
324 mother-infant dyads (98.2%) were included (Fig. 1).
Fig. 1 Flow chart of inclusions and exclusions of mother-infant dyads
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Median (inter quartile range)
Maternal age during delivery (years) 33 (29–36) 32 (29–36) 33 (29–36) 0.59
Duration of observation mother (days) 4 (3–5) 4 (3–6) 4 (3–5) 0.28
Duration of observation infant (days) 4 (3–5) 4 (3–5) 4 (3–5) 0.14
n (%)
Marital status 0.80
Married/living together 275 (85.9) 121 (85.2) 154 (86.5)
Living Apart Together 17 (5.3) 7 (4.9) 10 (5.6)
Single 28 (8.8) 14 (9.9) 14 (7.9)
Unknown 4 1 3
Smoking 31 (9.8) 16 (11.6) 15 (8.5) 0.36
Unknown 9 5 4
Type of psychotropic medication 0.37
Solely antidepressant 291 (89.8) 126 (88.1) 165 (91.2)
Antidepressant and other type of psychotropic drug 33 (10.2) 17 (11.9) 16 (8.8)
Dosage of antidepressant 0.003
Below minimal effective daily dosage 20 (6.2) 8 (5.6) 12 (6.6)
Minimal effective daily dosage 146 (45.2) 50 (35.2) 96 (53.0)
Above minimal effective daily dosage 157 (48.6) 84 (59.2) 73 (40.3)
Unknown 1
Primiparous 144 (44.4) 65 (45.5) 79 (43.6) 0.75
HADSa
Anxiety scale elevated 131 (42.5) 75 (55.1) 67 (39.0) 0.02
Depression scale elevated 93 (30.2) 68 (50.0) 63 (36.6) 0.01
One or both scales elevated 142 (46.1) 75 (55.1) 67 (39.0) 0.01
Unknown 16 7 9
Gender infant male 163 (50.3) 78 (54.5) 85 (47.0) 0.18
Type of birth 0.07
Vaginal, non-instrumental 236 (72.8) 97 (67.8) 139 (76.8)
Vaginal, instrumental 37 (11.4) 16 (11.2) 21 (11.6)
Caesarean Section 51 (15.7) 30 (21.0) 21 (11.6)
Type of feeding 0.02
Breastfeeding or mixed feeding 250 (77.4) 101 (71.1) 149 (82.3)
Exclusively formula 73 (22.6) 41 (28.9) 32 (17.7)
Unknown 1
Prematurity 30 (9.3) 13 (7.0) 17 (9.4) 0.93
Finnegan score, highest during observation <0.001
< 4 130 (40.1) 30 (21.0) 100 (55.2)
4–8 156 (48.1) 80 (55.9) 76 (42.0)
≥ 8 38 (11.7) 33 (23.1) 5 (2.8)
aHospital anxiety and depression scale
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Of these mothers, 304 mothers (93.8%) delivered in our
hospital, 13 mothers (4.0%) delivered at home and 7
mothers (2.2%) delivered in another hospital. The mater-
nal and neonatal characteristics are presented in Table 1.
Three mothers (0.9%) decided to go home before medical
discharge, all after at least 48 h of observation. Of the 324
mothers, 310 (95.7%) were known with an affective
disorder, some in combination with other psychiatric
disorders. Of the 291 mothers who solely used an anti-
depressant, 209 used an selective serotonin reuptake
inhibitors, 32 a serotonin norepinephrine reuptake in-
hibitors, 35 a noradrenergic and specific serotonergic
antidepressants and 1 a norepinephrine-dopamine re-
uptake inhibitor. Fourteen mothers used a combination
of antidepressants. See Appendix for an overview of
antidepressants used in our study population.
Interventions
Of the 324 mother-infant dyads, a total of 143 dyads
(61.1%) needed one or more intervention. One interven-
tion was performed in 70.6% of dyads. In 24.5% two and
in 4.9% three or four interventions were performed.
In 76 mothers (23.5%) the psychotropic medication
was adjusted. The main reasons were symptoms of de-
pression or anxiety and sleeping difficulties. No mothers
had to be admitted to the psychiatric department. Nine
infants (2.8%) underwent additional tests due to indistinct-
ness about the origin of neonatal symptoms. Additional
testing, which included blood tests, brain ultrasounds, a
chest radiograph and electroencephalography excluded
other pathology where after poor neonatal adaptation was
diagnosed in all nine infants. The pediatrician diagnosed
poor neonatal adaptation in 76 infants (23.5%). These
infants showed mild symptoms of sleeping- as well as
feeding difficulties, tremors and jitteriness. One infant was
treated with phenobarbital as these symptoms of restless-
ness were more severe and prolonged. All other infants
were treated with supportive measures. External support
was organized for eight mother-infant dyads (2.5%), which
consisted of psychiatric home care, social welfare and sup-
port regarding infant development.
Time to interventions
The time to interventions are presented in Fig. 2. In 63
of the 143 dyads in which an intervention was per-
formed, the time of at least one intervention was un-
known. Thus, we analyzed time to the final intervention
in 80 mother-infant dyads. In 67.5% of these dyads one
intervention was performed and in 32.5% multiple inter-
ventions were performed. In 6 of the dyads (7.5%), the
final intervention was performed within 12 h, in 28
(35%) between 13 and 24 h, in 26 (32.5%) between 25
and 48 h, in 16 (20.0%) between 49 and 72 and in 4
(5.0%) after 72 h postpartum.
Base-line characteristics were compared between
mother-infant dyads in which the final intervention was
performed within 48 h and dyads in which the final
intervention was performed after 48 h postpartum
(Table 2). This revealed no statistically significant
differences.
Discussion
To the best of our knowledge, this is the first study pre-
senting data on medical interventions during the course
of postpartum observation of mother-infant dyads ex-
posed to selective antidepressants during pregnancy. In
61% of all dyads one or more interventions were per-
formed. The most prevalent interventions were adjust-
ment of psychotropic medication and treatment of poor
neonatal adaptation. As expected, the Finnegan scores
Fig. 2 Time to interventions. a. Data on the time of medication adjustment were missing in 18 mother-infant dyads. b. Data on the time of
treatment of poor neonatal adaptation were missing in 27 mother-infant dyads
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Table 2 Comparison of base-line characteristics between mother-infant dyads whereby the final intervention was performed within









Maternal age during delivery (years) 33.3 (4.7) 31.9 (4.3) 0.24
Median (interquartile range)
Duration of observation mother (days) 4 (3–5) 4 (3.3–5) 0.68
Duration of observation infant (days) 4 (3–5) 4 (3.3–5) 0.79
n (%) Odds ratio
95% CI
Marital status 0.26*
Single 6 (60.0) 4 (40.0) 1 (ref)
Married/living together/LATa 54 (77.1) 16 (22.9) 0.44
0.11–1.77
Smoking 1.00*
No 55 (76.4) 17 (23.6) 1 (ref)
Yes 5 (83.3) 1 (16.7) 0.65
0.07–5.93
Unknown 0 2
Type of psychotropic medication 1.00*
Solely antidepressant 54 (75.0) 18 (25.0) 1 (ref)
Antidepressant and other type of psychotropic drug 6 (75.0) 2 (25.0) 1.00
0.19–5.40
Dosage 0.19
Minimal or below minimal effective daily
dosage
25 (83.3) 5 (16.7) 1 (ref)
Above minimal effective daily dosage 35 (70.0) 15 (30.0) 0.47
0.15–0.69
Parity 0.16
Primiparous 32 (82.1) 7 (17.9) 1 (ref)
Multiparous 28 (68.3) 13 (31.7) 2.12
0.74–6.06
HADSb
Anxiety scale not elevated 27 (73.0) 10 (27.0) 1 (ref) 0.74
Anxiety scale elevated 32 (76.2) 10 (23.8) 0.84
0.31–2.33
Depression scale not elevated 32 (74.4) 11 (25.6) 1 (ref) 0.95
Depression scale elevated 27 (75.0) 9 (25.0) 0.97
0.35–2.69
No scales elevated 24 (75.0) 8 (25.0) 1 (ref) 0.96




Male 32 (72.7) 12 (27.3) 1 (ref)
Female 28 (77.8) 8 (22.2) 0.76
0.27–2.13
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of infants in the group whereby interventions were
performed were higher (p = <0.001) and the level of
symptoms of anxiety and depression was higher in the
intervention group. Also, in mother-infant dyads
whereby an intervention was performed, mothers used
a relatively higher antidepressant dosage. The type of
underlying psychiatric disorder and severity of psychi-
atric symptoms might attribute to this relationship.
PNA does not seem to be related to the antidepressant
dosage [13, 24]. In mother-infant dyads whereof the
infants were formula-fed, the intervention rate was
higher. An earlier study of our research group showed
that formula-fed infants develop more symptoms of
poor neonatal adaptation, which could explain this
finding [24]. However, other factors, such as the type of
psychotropic drugs (some are not compatible with
breastfeeding) and severity of psychiatric disorder
might also attribute to this relationship. The other
base-line characteristics did not differ significantly.
Given the high prevalence of interventions, we would
advise to observe all selective antidepressant-exposed
mother-infant dyads. Thereby, the observational setting
is a matter of debate. There are several disadvantages of
hospital admission, including the risk of infection and
lack of privacy. However, interventions that were most
prevalent; adjustment of the psychotropic medication
and establishment of poor neonatal adaptation, have to
be performed by professionals [5, 25]. In the absence of
specialized home care in a country, hospital admission
is indicated.
Based on our results, we would advise to observe
mother-infant dyads for 48 h. This advice is based on
our finding that the final intervention was performed
within 48 h in the majority of dyads (75%), while after
an observational period of 24 h this percentage was
only 43%. However, in 25% of mother-infant dyads the
final intervention was performed after 48 h postpar-
tum. Base-line characteristics of this group of dyads
did not differ from base-line characteristics of dyads in
which the final intervention was performed within
48 h postpartum.
It is especially difficult to determine the duration of
the observational period for mother-infant dyads with
no other indication for hospital admission apart from
the exposure to selective antidepressants. Therefore, we
performed a post-hoc analysis whereby we excluded
dyads with an additional indication for hospital admis-
sion directly postpartum, such as a caesarean section or
prematurity (n = 165). Of the remaining 159 dyads, 60
(37.7%) needed one or more intervention. The preva-
lence of interventions was higher in the group of dyads
with an additional indication for hospital admission
compared to the group of dyads whereby selective
antidepressant-exposure was the only indication for
hospital admission (p 0.02). A possible explanation for
this finding might be that indications for hospital stay,
such as prematurity or fluxus might be associated with
selective antidepressant exposure [15, 26].
By interpretation of our results, it is important to
hold into account that the percentage of mother-infant
Table 2 Comparison of base-line characteristics between mother-infant dyads whereby the final intervention was performed within
48 h and after 48 h postpartum (Continued)
Type of birth 0.66
Vaginal 45 (76.3) 14 (23.7) 1 (ref)
Caesarean Section 15 (71.4) 6 (28.6) 1.29
0.42–3.94
Type of feeding 0.67
Breastfeeding or mixed feeding 42 (73.7) 15 (26.3) 1 (ref)
Exclusively formula 18 (78.2) 5 (21.7) 0.78
0.25–2.46
Gestational age 0.57*
< 37 weeks 4 (100.0) 0 (0.0) Not possible to calculate
≥ 37 weeks 56 (73.7) 20 (26.3)
Finnegan score, highest during observation 0.50*
< 4 12 (85.7) 2 (14.3) 1 (ref)
≥ 4 48 (72.7) 18 (27.3) 2.25
0.46–11.06
Odds ratios and 95% confidence intervals are presented
*Calculated with Fisher exact test
aLAT: Living apart together
bHADS: Hospital anxiety and depression scale
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dyads whereby an intervention was performed is based
on 5 types of neonatal and maternal interventions
which differ in type and underlying medical problem.
This also accounts for the time to interventions,
whereby 4 interventions were analyzed.
This study has several limitations. First of all, there
were missing data due to the observational design of
this study. However, there is no indication that these
data were selective. Therefore the reliability of our re-
sults is not likely to be affected. Furthermore, hospital
admission entails the risk of over diagnosis; some
observed effects, which resulted in additional testing
or therapy, would not have been observed nor have
led to problems in the home setting. Thereby a longer
observational period might result in a higher risk of
over diagnosis. Apart from the detriment for mother
and infant, this may also have affected our study re-
sults by increasing the prevalence of interventions.
Also, it is important to realize, that this study was
performed in a center of expertise for pregnancy and
psychiatry. All women were evaluated by a psych-
iatrist and all infants by a pediatrician. This thorough
examination may have resulted in an accurate preva-
lence. However it is plausible that the prevalence of
interventions in this study is higher compared to
centers without this specialized care. Furthermore,
mother-infant dyads which had been transferred to
another hospital were excluded because there was no
or a limited observational period in our hospital. As
this transfer was based on severe maternal or neonatal
pathology in three mother-infant dyads, this may have
lead to a relative underestimation of the prevalence of
interventions.
Conclusions
In conclusion, in mother-infant dyads exposed to se-
lective antidepressants during pregnancy, the prevalence
of medical interventions was 61%. The most prevalent
interventions were adjustment of psychotropic medica-
tion and treatment of poor neonatal adaptation. The
high prevalence and type of medical interventions re-
quires professional observation of all mother-infant
dyads by a multidisciplinary team including a psych-
iatrist, pediatrician and trained nurses. In the absence of
specialized home care, hospital admission is indicated.
An observational period of 48 h seems sufficient for
most mother-infant dyads. Further studies that examine
predictors of intervention during observation or predic-
tors of a prolonged observation, would be of additional
value. If these predictors are known, it might be possible
to provide an advise regarding the type and duration of
observation on individual basis. In addition, a cost-
effectiveness analysis would also be essential for devel-
opment of a guideline.
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CI: Confidence interval; HADS: Hospital anxiety and depression scale;
LAT: Living apart together; OR: Odds ratio; PPHN: Persistent pulmonary
hypertension of the newborn





Paroxetine and mirtazapine 3
Paroxetine and olanzapine 2
Paroxetine and risperidone 1
Sertraline 71
Sertraline and mitrazapine 3
Sertraline and haloperidol 3
Sertraline and quetiapine 1
Sertraline and flupentixol 1
Fluoxetine 18
Fluoxetine and mirtazapine 1
Fluoxetine and quetiapine 1
Citalopram 58
Citalopram and mirtazapine 4
Citalopram and amitryptiline 1
Citalopram, amitriptyline and mirtazapine 1
Citalopram and olanzapine 1
Citalopram and pipamperone 1
Citalopram and haloperidol 1
Citalopram and lithium 1
Citalopram and oxaxepam 1
Venlafaxine 32
Venlafaxine, mirtazapine and haloperidol 1
Venlafaxine and haloperidol 1
Venlafaxine and quetiapine 5
Venlafaxine and olanzapine 1
Fluvoxamine 4
Fluvoxamine and lithium 1
Mirtazapine 35
Mirtazapine and clompiramine 1
Mirtazapine and haloperidol 4
Mirtazapine and risperidone 2
Mirtazapine and quetiapine 1
Mirtazapine and perfenazine 1
Mirtazapine and flurazepam 1
Bupropion 1
Bupropion and quetiapine 1
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